With no marketed drugs, Intellia Therapeutics, Inc.’s NTLA investors are likely to focus on pipeline progress when it reports fourth-quarter results.The company’s earnings missed estimates in two of the last four quarters and beat the same twice with the average negative surprise being 10.64%. In the last reported quarter, Intellia delivered an earnings surprise of 12.96%.Shares of Intellia have soared 392.7% in the past year compared with the industry‘s increase of 14.9%.Factors to NoteIntellia’s top line mainly comprises revenues recognized from the progress of its pipeline under existing collaboration with Novartis NVS and Regeneron REGN.The company reported $51.4 million of collaboration revenues in the first nine months of 2020, reflecting a year-over-year increase of 59.8%. However, revenues may vary from quarter to quarter as it is subject to achievement of pre-defined milestones.In November, the company initiated its first clinical study. The early-stage study will evaluate single dose of its gene editing candidate, NTLA-2001, as potential treatment for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a rare disease leading to nerve damage and cardiomyopathy. Investors will likely look for any initial data update from the study on the fourth-quarter earnings call.The company has several other gene editing pipeline candidates in pre-clinical stage. The company plans to submit an investigational new drug application for NTLA-5001 and NTLA-2002 as potential gene editing therapies for acute myeloid leukemia and hereditary angioedema, respectively, in 2021.Increased pre-clinical and clinical activities as well as preparation for regulatory activities are likely to have driven operating expenses during the fourth quarter.We expect management to provide a brief update on the progress with its pre-clinical pipeline on its earnings call.Earnings WhispersOur proven model does not conclusively predict an earnings beat for Intellia this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 48 cents) and the Zacks Consensus Estimate (loss of 57 cents) is +15.97%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: Intellia carries a Zacks Rank #4 (Sell).Intellia Therapeutics, Inc. Price and Consensus Intellia Therapeutics, Inc. price-consensus-chart | Intellia Therapeutics, Inc. QuoteA Stock That Warrants a Look Here is a biotech stock that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.Moderna, Inc. MRNA has an Earnings ESP of +0.57% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.The Hottest Tech Mega-Trend of AllLast year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.See Zacks' 3 Best Stocks to Play This Trend >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research